Cochrane Review: Cenobamate add-on therapy for drug-resistant focal epilepsy

Zusammenfassung

Cenobamat als Zusatztherapie bei medikamentenresistenter fokaler Epilepsie - Brigo, F - 2024 \| Cochrane Library [Skip to Content](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014941.pub2/full/de#main-content) [Close cookies message](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014941.pub2/full/de#) Cookies Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off

Kerninformationen

f Systematic reviews](https://www.cochranelibrary.com/en/about/about-cochrane-reviews) Review - Intervention Collapse all Expand all ## Abstract available in ### Background Although most people with epilepsy achieve complete seizure cessation, approximately one‐third of those with the conditio...

ith one or more ASMs. ### Search methods We searched the Cochrane Register of Studies (CRS Web) and MEDLINE Ovid (September 2022). In addition, we contacted the manufacturer of cenobamate and experts in the field to enquire after any ongoing or unpublished studies. ### Selection criteria RCTs co...

n‐to‐treat approach for our primary analyses. For each outcome we estimated summary risk ratios (RRs) with their 95% confidence intervals (CIs). We summarised the estimates of effects and certainty of the evidence for each outcome in a summary of findings table. ### Main results We included two st...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen